Skip to main content

Table 3 Results of the different cost-effectiveness analyses

From: Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial

 

Unadjusted

Adjusted

QLQ-C30

bCBT

CAU

bCBT

CAU

bCBT

CAU

Costs

Mean

6001

6165

6001

6165

6001

6165

95% CI

4552 to 7664

4657 to 7850

4552 to 7664

4657 to 7850

4552 to 7664

4657 to 7850

Incremental costs

Mean

−164

−164

−164

95% CI

−2018 to 2502

−2018 to 2502

−2018 to 2502

QALYs

Mean

1.027

0.913

0.984

0.957

1.107

1.074

 

95% CI

0.966 to 1.083

0.839 to 0.980

0.941 to 1.028

0.912 to 1.001

1.074 to 1.135

1.046 to 1.100

Incremental QALYs

Mean

0.114

0.028

0.033

95% CI

0.026 to 0.206*

−0.031 to 0.090

−0.012 to 0.072

ICER

 

€-1081 / QALY

€2049 / QALY

€-6189 / QALY

INMB at WTP of 0

Mean

€164

€-57

€164

95% CI

€-2018 to €2502

€-2709 to €2370

€-2081 to 2419

INMB at WTP of €20,000

Mean

€2403

€498

€807

95% CI

€-893 to €5454

€-2514 to €3269

€-1898 to €3249

INMB at WTP of €50,000

Mean

€5761

€1331

€1770

95% CI

€386 to €11,274*

€-3189 to €5773

€-1322 to €5064

  1. NOTE. Unadjusted and adjusted cost-effectiveness analyses used QALYs calculated from EQ-5D utilities, while the QLQ-C30 analysis used QALYs calculated from EORTC QLQ-C30 utilities. Estimates in the adjusted cost-effectiveness analysis were adjusted for baseline EQ-5D utility scores. Confidence intervals were obtained after bootstrapping with 1000 replications
  2. Abbreviations: bCBT blended cognitive behaviour therapy, CAU care as usual, QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, WTP willingness to pay, QALY quality adjusted life-year
  3. *Significant difference between the two conditions (p < 0.05)